SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Clinical trials for SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS trials appear
Sign up with your email to follow new studies for SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Nasal spray could slow brain inflammation in progressive MS
Disease control Recruiting nowThis study tests a nasal spray called foralumab in people with non-active secondary progressive multiple sclerosis (SPMS), a form of MS that worsens over time. The goal is to see if the drug is safe and can reduce brain inflammation measured by special scans. About 54 adults aged…
Matched conditions: SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE2 • Sponsor: Tiziana Life Sciences LTD • Aim: Disease control
Last updated May 17, 2026 01:19 UTC
-
Could a stem cell transplant stop MS in its tracks?
Disease control Recruiting nowThis study compares a stem cell transplant (AHSCT) to the best standard treatments for people with relapsing multiple sclerosis that hasn't responded to other therapies. About 156 participants will be randomly assigned to one of the two groups and followed for six years. The goal…
Matched conditions: SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated May 17, 2026 01:19 UTC
-
Could a cancer drug tame multiple sclerosis? new trial launches
Disease control Recruiting nowThis study tests whether a drug called ixazomib, currently used for cancer, is safe for people with multiple sclerosis (MS). About 72 adults with relapsing-remitting or progressive MS will take either ixazomib capsules or a placebo for up to 24 months. Researchers will monitor si…
Matched conditions: SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE1 • Sponsor: Queen Mary University of London • Aim: Disease control
Last updated May 12, 2026 13:39 UTC
-
New pill aims to slow MS progression in 990-patient global trial
Disease control Recruiting nowThis study tests an oral drug called orelabrutinib against a placebo in about 990 adults aged 18-60 with non-active secondary progressive multiple sclerosis (SPMS). The goal is to see if the drug can delay worsening disability over 12 to 60 months. Participants are randomly assig…
Matched conditions: SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: Zenas BioPharma (USA), LLC • Aim: Disease control
Last updated May 06, 2026 16:14 UTC